XBB: the chosen one from SARS-CoV-2 homologous recombination

Qi Chen; Pan-Deng Shi; Cheng-Feng Qin

doi:10.1093/lifemedi/lnae002

Life Medicine ›› 2024, Vol. 3 ›› Issue (2) : lnae002 DOI: 10.1093/lifemedi/lnae002

News & Opinions

XBB: the chosen one from SARS-CoV-2 homologous recombination

Author information +

History +

PDF (1882KB)

Cite this article

Download citation ▾

Qi Chen, Pan-Deng Shi, Cheng-Feng Qin. XBB: the chosen one from SARS-CoV-2 homologous recombination. Life Medicine, 2024, 3(2): lnae002 DOI:10.1093/lifemedi/lnae002

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Turakhia Y , Thornlow B , Hinrichs A , et al. Pandemic-scale phylogenomics reveals the SARS-CoV-2 recombination landscape. Nature 2022; 609: 994- 7.

[2]	Tamura T , Ito J , Uriu K , et al; Genotype to Phenotype Japan (G2P-Japan) Consortium . Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. Nat Commun 2023; 14: 2800.

[3]	Imai M , Ito M , Kiso M , et al. Efficacy of antiviral agents against omicron subvariants BQ11 and XBB. N Engl J Med 2023; 388: 89- 91.

[4]	Zhang X , Chen L-L , Ip JD , et al. Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines. Lancet Microbe 2023; 4: e131.

[5]	Yang J , Hong W , Lei H , et al. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA5 infection. Signal Transduct Target Ther 2023; 8: 252.